WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 47.50
-1.34 (-2.74%)
Sep 10, 2026, 4:08 PM HKT
WuXi Biologics Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 23,624 | 21,790 | 18,675 | 17,034 | 15,269 | 10,290 |
Revenue Growth | 8.42% | 16.68% | 9.63% | 11.56% | 48.38% | 83.34% |
Gross Profit Gross Profit Growth | 11,214 | 10,019 | 7,651 | 6,828 | 6,724 | 4,829 |
Operating Income Operating Income Growth | 7,650 | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 |
Net Income Net Income Growth | 5,009 | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 |
Earnings Per Share EPS Growth | 1.18 | 1.16 | 0.78 | 0.77 | 1.01 | 0.77 |
EPS Growth | 2.05% | 47.93% | 1.55% | -23.50% | 31.17% | 92.50% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Xdc Xdc Growth | 6,945 | 5,944 | 4,052 | 2,124 | 990.42 |
Biologics Biologics Growth | 19,075 | 18,139 | 16,508 | 16,032 | 15,005 |
Adjustments and Eliminations Adjustments and Eliminations Growth | -2,396 | -2,293 | -1,885 | -1,122 | -726.52 |
Total Total Growth | 23,624 | 21,790 | 18,675 | 17,034 | 15,269 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 13,028 | 15,733 | 10,710 | 11,243 | 8,714 | 11,126 |
Total Debt Total Debt Growth | 2,726 | 3,104 | 4,940 | 4,561 | 4,422 | 4,295 |
Net Cash (Debt) Net Cash Growth | 10,303 | 12,629 | 5,770 | 6,682 | 4,293 | 6,831 |
Net Cash Growth | -18.42% | 118.87% | -13.65% | 55.66% | -37.16% | 32.68% |
Net Cash Per Share Net Cash Per Share Growth | 2.47 | 3.02 | 1.36 | 1.54 | 0.98 | 1.54 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | - | 6,341 | 5,217 | 4,668 | 5,542 | 3,431 |
Capital Expenditures CapEx Growth | - | -3,685 | -3,930 | -4,046 | -5,868 | -6,508 |
Free Cash Flow Free Cash Flow Growth | - | 2,656 | 1,288 | 622.14 | -326.72 | -3,077 |
Free Cash Flow Growth | - | 106.25% | 106.97% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 47.47% | 45.98% | 40.97% | 40.08% | 44.04% | 46.93% |
Operating Margin | 32.38% | 30.50% | 24.55% | 23.09% | 28.49% | 30.81% |
Pretax Margin | 31.10% | 33.30% | 25.89% | 24.50% | 35.09% | 38.81% |
Profit Margin | 21.20% | 22.53% | 17.97% | 19.96% | 28.95% | 32.93% |
FCF Margin | - | 12.19% | 6.89% | 3.65% | -2.14% | -29.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 34.74 | 23.79 | 20.19 | 33.37 | 50.61 | 93.99 |
Forward PE | 23.91 | 21.64 | 17.09 | 22.71 | 37.41 | 77.91 |
P/FCF Ratio | - | 43.97 | 52.62 | 182.37 | - | - |
PS Ratio | 7.15 | 5.36 | 3.63 | 6.66 | 14.65 | 30.95 |